The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology
Open accessAbstract
MicroRNAs play important roles in regulating the gene expression and life cycle of cancer cells. In particular, miR-21, an oncogenic miRNA is a major player involved in tumor initiation, progression, invasion and metastasis in several cancers, including triple negative breast cancer (TNBC). However, delivery of therapeutic miRNA or anti-miRNA specifically into cancer cells in vivo without collateral damage to healthy cells remains challenging. We report here the application of RNA nanotechnology for specific and efficient delivery of anti-miR-21 to block the growth of TNBC in orthotopic mouse models. The 15 nm therapeutic RNA nanoparticles contains the 58-nucleotide (nt) phi29 pRNA-3WJ as a core, a 8-nt sequence complementary to the seed region of miR-21, and a 39-nt epidermal growth factor receptor (EGFR) targeting aptamer for internalizing RNA nanoparticles into cancer cells via receptor mediated endocytosis. The RNase resistant and thermodynamically stable RNA nanoparticles remained intact after systemic injection into mice and strongly bound to tumors with little or no accumulation in healthy organs 8 h postinjection, and subsequently repressed tumor growth at low doses. The observed specific cancer targeting and tumor regression is a result of several key attributes of RNA nanoparticles: anionic charge which disallows nonspecific passage across negatively charged cell membrane; "active" targeting using RNA aptamers which increases the homing of RNA nanoparticles to cancer cells; nanoscale size and shape which avoids rapid renal clearance and engulfment by lung macrophages and liver Kupffer cells; favorable biodistribution profiles with little accumulation in healthy organs, which minimizes nonspecific side effects; and favorable pharmacokinetic profiles with extended in vivo half-life. The results demonstrate the clinical potentials of RNA nanotechnology based platform to deliver miRNA based therapeutics for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Garzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600
Detection of microRNA Expression in Human Peripheral Blood Microvesicles
Hunter, M. P., Ismail, N., Zhang, X., Aguda, B. D., Lee, E. J., Yu, L., Xiao, T., Schafer, J., Lee, M.-L. T., Schmittgen, T. D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003694 · Cited by 1,452
miRNAs, Cancer, and Stem Cell Division
Croce, C. M., & Calin, G. A. (2005) · Cell · doi:10.1016/j.cell.2005.06.036 · Cited by 1,329
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831
The emerging field of RNA nanotechnology
Guo, P. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.231 · Cited by 718
Self-citationTabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
Self-assembled RNA interference microsponges for efficient siRNA delivery
Lee, J. B., Hong, J., Bonner, D. K., Poon, Z., & Hammond, P. T. (2012) · Nature Materials · doi:10.1038/nmat3253 · Cited by 494
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Shu, D., Shu, Y., Haque, F., Abdelmawla, S., & Guo, P. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.105 · Cited by 435
Self-citationA single-stranded architecture for cotranscriptional folding of RNA nanostructures
Geary, C., Rothemund, P. W. K., & Andersen, E. S. (2014) · Science · doi:10.1126/science.1253920 · Cited by 361
Zhang, H.-G., & Grizzle, W. E. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.09.027 · Cited by 352
Inter-RNA Interaction of Phage φ29 pRNA to Form a Hexameric Complex for Viral DNA Transportation
Guo, P., Zhang, C., Chen, C., Garver, K., & Trottier, M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80124-0 · Cited by 351
Self-citationA Small Viral RNA Is Required for in Vitro Packaging of Bacteriophage φ29 DNA
Guo, P., Erickson, S., & Anderson, D. (1987) · Science · doi:10.1126/science.3107124 · Cited by 312
Self-citationRNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Single-Molecule Measurements of the Persistence Length of Double-Stranded RNA
Abels, J. A., Moreno-Herrero, F., van der Heijden, T., Dekker, C., & Dekker, N. H. (2005) · Biophysical Journal · doi:10.1529/biophysj.104.052811 · Cited by 269
Stable RNA nanoparticles as potential new generation drugs for cancer therapy
Shu, Y., Pi, F., Sharma, A., Rajabi, M., Haque, F., Shu, D., Leggas, M., Evers, B. M., & Guo, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.006 · Cited by 244
Self-citationQi, L., Bart, J., Tan, L. P., Platteel, I., Sluis, T. V. D., Huitema, S., Harms, G., Fu, L., Hollema, H., & Berg, A. V. D. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-163 · Cited by 229
Multifunctional RNA Nanoparticles
Afonin, K. A., Viard, M., Koyfman, A. Y., Martins, A. N., Kasprzak, W. K., Panigaj, M., Desai, R., Santhanam, A., Grabow, W. W., Jaeger, L., et al. (2014) · Nano Letters · doi:10.1021/nl502385k · Cited by 219
microRNA Replacement Therapy for Cancer
Henry, J. C., Azevedo-Pouly, A., & Schmittgen, T. D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0548-9 · Cited by 197
Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers
Haque, F., Shu, D., Shu, Y., Shlyakhtenko, L. S., Rychahou, P. G., Mark Evers, B., & Guo, P. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.010 · Cited by 193
Self-citationA Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
Esposito, C. L., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., de Franciscis, V., & Cerchia, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024071 · Cited by 182
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine
Afonin, K. A., Grabow, W. W., Walker, F. M., Bindewald, E., Dobrovolskaia, M. A., Shapiro, B. A., & Jaeger, L. (2011) · Nature Protocols · doi:10.1038/nprot.2011.418 · Cited by 181
AFM for analysis of structure and dynamics of DNA and protein–DNA complexes
Lyubchenko, Y. L., & Shlyakhtenko, L. S. (2009) · Methods · doi:10.1016/j.ymeth.2008.09.002 · Cited by 174
Atomic Force Microscopy Imaging of Double Stranded DNA and RNA
Lyubchenko, Y. L., Gall, A. A., Shlyakhtenko, L. S., Harrington, R. E., Jacobs, B. L., Oden, P. I., & Lindsay, S. M. (1992) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.1992.10508670 · Cited by 174
Shu, Y., Haque, F., Shu, D., Li, W., Zhu, Z., Kotb, M., Lyubchenko, Y. L., & Guo, P. (2013) · RNA · doi:10.1261/rna.037002.112 · Cited by 161
Self-citationImaging of nucleic acids with atomic force microscopy
Lyubchenko, Y. L., Shlyakhtenko, L. S., & Ando, T. (2011) · Methods · doi:10.1016/j.ymeth.2011.02.001 · Cited by 157
Khisamutdinov, E. F., Li, H., Jasinski, D. L., Chen, J., Fu, J., & Guo, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku516 · Cited by 138
Self-citationDibrov, S. M., McLean, J., Parsons, J., & Hermann, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017999108 · Cited by 137
Guo, P., Haque, F., Hallahan, B. J., Reif, R. D., & Li, H. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0350 · Cited by 132
Self-citationLiu, J., Guo, S., Cinier, M., Shlyakhtenko, L. S., Shu, Y., Chen, C., Shen, G., & Guo, P. (2010) · ACS Nano · doi:10.1021/nn1024658 · Cited by 129
Self-citationCastoldi, M., Schmidt, S., Beneš, V., Hentze, M., & Muckenthaler, M. (2008) · Nature Protocols · doi:10.1038/nprot.2008.4 · Cited by 129
Zhang, H., Endrizzi, J. A., Shu, Y., Haque, F., Sauter, C., Shlyakhtenko, L. S., Lyubchenko, Y. L., Guo, P., & Chi, Y. (2013) · RNA · doi:10.1261/rna.037077.112 · Cited by 129
Self-citationCo-transcriptional Assembly of Chemically Modified RNA Nanoparticles Functionalized with siRNAs
Afonin, K. A., Kireeva, M. L., Grabow, W. W., Kashlev, M., Jaeger, L., & Shapiro, B. A. (2012) · Nano Letters · doi:10.1021/nl302302e · Cited by 124
Abdelmawla, S., Guo, S., Zhang, L., Pulukuri, S. M. K., Patankar, P. P., Conley, P., Trebley, J., Guo, P., & Li, Q. (2011) · Molecular Therapy · doi:10.1038/mt.2011.35 · Cited by 124
Self-citationRNA interference therapeutics for cancer: Challenges and opportunities (Review)
Bora, R. S. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.871 · Cited by 123
Khisamutdinov, E. F., Jasinski, D. L., & Guo, P. (2014) · ACS Nano · doi:10.1021/nn5006254 · Cited by 123
Self-citationRNAi‐Microsponges Form through Self‐Assembly of the Organic and Inorganic Products of Transcription
Shopsowitz, K. E., Roh, Y. H., Deng, Z. J., Morton, S. W., & Hammond, P. T. (2013) · Small · doi:10.1002/smll.201302676 · Cited by 112
Eldh, M., Bagge, R. O., Lässer, C., Svanvik, J., Sjöstrand, M., Mattsson, J., Lindnér, P., Choi, D., Gho, Y. S., & Lötvall, J. O. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-962 · Cited by 105
Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Srivastava, A., Filant, J., Moxley, K. M., Sood, A. K., McMeekin, S., & Ramesh, R. (2015) · Current Gene Therapy · doi:10.2174/1566523214666141224100612 · Cited by 95
RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
Lee, T. J., Haque, F., Shu, D., Yoo, J. Y., Li, H., Yokel, R. A., Horbinski, C., Kim, T. H., Kim, S.-H., Kwon, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3632 · Cited by 92
Self-citationPolymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing
Cheng, C. J., & Saltzman, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300081s · Cited by 92
Clinical and pathologic aspects of basal-like breast cancers
Fadare, O., & Tavassoli, F. A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1038 · Cited by 90
Jasinski, D. L., Khisamutdinov, E. F., Lyubchenko, Y. L., & Guo, P. (2014) · ACS Nano · doi:10.1021/nn502160s · Cited by 89
Self-citationExtracellular RNA mediates and marks cancer progression
Redzic, J. S., Balaj, L., van der Vos, K. E., & Breakefield, X. O. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.010 · Cited by 87
Shu, D., Khisamutdinov, E. F., Zhang, L., & Guo, P. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt885 · Cited by 83
Self-citationGriveau, A., Béjaud, J., Anthiya, S., Avril, S., Autret, D., & Garcion, E. (2013) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2013.05.049 · Cited by 80
Self-assembly of free-standing RNA membranes
Han, D., Park, Y., Kim, H., & Lee, J. B. (2014) · Nature Communications · doi:10.1038/ncomms5367 · Cited by 72
Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles
Kim, J., Yeom, J., Ko, J., Han, M. S., Lee, K., Na, S.-Y., & Bae, J. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.07.014 · Cited by 69
Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ from Three RNA Fragments
Binzel, D. W., Khisamutdinov, E. F., & Guo, P. (2014) · Biochemistry · doi:10.1021/bi4017022 · Cited by 69
Self-citationTakahashi, M. M., Yamada, N., Hatakeyama, H., Murata, M., Sato, Y., Minakawa, N., Harashima, H., & Matsuda, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt823 · Cited by 55
RNAi Therapeutics: How Likely, How Soon?
Robinson, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020028 · Cited by 53
Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 44
Future Opportunities in Cancer Nanotechnology—NCI Strategic Workshop Report
Grodzinski, P. A., & Farrell, D. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2787 · Cited by 34
Li, H., Rychahou, P. G., Cui, Z., Pi, F., Evers, B. M., Shu, D., Guo, P., & Luo, W. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0525 · Cited by 10
Self-citation
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Recent Advances in Aptamer Discovery and Applications
Zhang, Y., Lai, B. S., & Juhas, M. (2019) · Molecules · doi:10.3390/molecules24050941 · Cited by 663
Pi, F., Binzel, D. W., Lee, T. J., Li, Z., Sun, M., Rychahou, P., Li, H., Haque, F., Wang, S., Croce, C. M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0012-z · Cited by 494
Self-citationVienberg, S., Geiger, J., Madsen, S., & Dalgaard, L. T. (2017) · Acta Physiologica · doi:10.1111/apha.12681 · Cited by 373
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
Self-citation
Metadata
- Authors
- Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W. E., Haque, F., Xu, R., & Guo, P.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-21
- Volume
- 9
- Issue
- 10
- Pages
- 9731-9740
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2224498017
- Cited by
- 270
- References
- 78
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.